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Abstract
Cystic fibrosis is associated with increased inflammatory responses to pathogen
challenge. Here we revisited the role of IL-1b in lung pathology using the
experimental F508del-CFTR murine model on C57BL/6 genetic background
(Cftrtm1eur or d/d), on double deficient for d/d and type 1 interleukin-1 receptor (d/d X
IL-1R12/2), and antibody neutralization. At steady state, young adult d/d mice did
not show any signs of spontaneous lung inflammation. However, IL-1R1 deficiency
conferred partial protection to repeated P. aeruginosa endotoxins/LPS lung
instillation in d/d mice, as 50% of d/d mice succumbed to inflammation, whereas all
d/d x IL-1R12/2 double mutants survived with lower initial weight loss and less
pulmonary collagen and mucus production, suggesting that the absence of IL-1R1
signaling is protective in d/d mice in LPS-induced lung damage. Using P.
aeruginosa acute lung infection we found heightened neutrophil recruitment in d/d
mice with higher epithelial damage, increased bacterial load in BALF, and
augmented IL-1b and TNF-a in parenchyma as compared to WT mice. Thus,
F508del-CFTR mice show enhanced IL-1b signaling in response to P. aeruginosa.
IL-1b antibody neutralization had no effect on lung homeostasis in either d/d or WT
mice, however P. aeruginosa induced lung inflammation and bacterial load were
diminished by IL-1b antibody neutralization. In conclusion, enhanced susceptibility
to P. aeruginosa in d/d mice correlates with an excessive inflammation and with
increased IL-1b production and reduced bacterial clearance. Further, we show that
neutralization of IL-1b in d/d mice through the double mutation d/d x IL-1R12/2 and
in WT via antibody neutralization attenuates inflammation. This supports the notion
that intervention in the IL-1R1/IL-1b pathway may be detrimental in CF patients.
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Introduction
Cystic fibrosis (CF) is an autosomal recessive genetic disease that affects 1
newborn out of 3,500 in the USA (WHO), and 1 per 2,000–3,000 in Europe, with
an average 40-year life expectancy. This pathology is caused by mutations within
the gene encoding the CFTR (Cystic Fibrosis Transmembrane Conductance
Regulator) chloride channel [1]. In humans, the most common mutation
(F508del) found in patients is a deletion of phenylalanine 508 (F508del) in the
CFTR chloride channel [2], the modified protein is not efficiently folded and is
rapidly degraded [3]. CF affects secretory epithelia from different organs, leading
to gastro-intestinal tract pathology, with a reduced pancreatic digestive enzyme
production [4] and chronic intestinal malabsorption [5]. CF mortality and
morbidity are mainly due to respiratory disease, characterized by the production
of abnormally viscous mucus, plugging of distal airways, and increased
susceptibility to chronic infections with opportunistic bacteria, excessive lung
inflammation, bronchiectasis and fibrosis leading to progressive loss of lung
function [6]. The exact molecular link between CFTR mutations and
hypersensitivity to infections remains unclear and controversial. In CF patients, S.
aureus predominates in the lung of children and teenagers, while P. aeruginosa
prevails in adults [7]. Exopolysaccharide-enriched biofilms produced by P.
aeruginosa increase the mucus viscosity, resistance to antibiotics and host immune
effectors. Chronic bacterial infections are common in CF patients and facilitates
lung inflammation, mucous obstruction and tissue remodeling, resulting in fatal
loss of function [1]. CF lungs display excessive inflammatory response, especially
with increased neutrophil recruitment [8], the mechanism of this phenomenon is
not adequately explained. However, intervention in this process likely will benefit
CF patients.
The role of the pro-inflammatory signaling cytokine Interleukin 1b (IL-1b) in
CF lung disease has been reported before. P. aeruginosa induces IL-1b or IL-18
production through NLRC4 inflammasome activation [9, 10]. P. aeruginosa
flagellin and highly acylated LPS is recognized by TLR5 [11] and TLR4 [12]
respectively. Human polymorphisms observed in the IL1B gene were associated
with CF disease [13]. CFTR deficient mice were found to be more susceptible to
acute [14, 15] and chronic [16] P. aeruginosa infection and display an exacerbated
inflammatory response to LPS and P. aeruginosa activated alveolar macrophages
from F508del mutant mice have enhanced expression of IL-1b [17, 18]. Huaux et
al recently showed a deregulated inflammatory and fibrotic response in F508del
mutant mice to bleomycin, which is IL-1R1 signaling dependent [19, 20].
Here we revisited the role of IL-1b in the resolution of P. aeruginosa infection,
in a murine model based on mice carrying the most common CF mutation
F508del CFTR [21–23]. In this study, we show that excessive activation of IL-1b
correlates with increased bacterial load, inflammation and lung damage in F508del
CFTR mice. Further, we show that IL-1b antibody neutralization attenuates the
inflammatory response to P. aeruginosa infection.
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Materials and Methods
Mice
Mice were on C57BL/6(J) background, wild type (WT), or homozygotes for
F508del CFTR mutation in the murine Cftr gene (Cftrtm1eur or d/d) [21–23], and
deficient for type 1 interleukin 1 receptor (d/d X IL-1R12/2) [24]. Mice, obtained
from Erasmus MC Rotterdam [21] were bred at TAAM – UPS 44, Orle´ans
(Institut Transgenose) and manipulated in an SPF zone. This study was carried
out in strict accordance with the recommendations of CNRS, and in the Guide
"Animaleries de laboratoire’’. The protocol was approved by the Committee on
the Ethics of CNRS of Orle´ans (Permit Number: CLE CCO 2012-042). All animals
are under daily inspection by the animal facility staff and the experimenters. All
efforts were made to minimize suffering.
IL-1b antibody administration
Mice were treated intraperitoneally, once a week for 8 weeks, with anti-IL-1b
antibody (Dr. Hermann Gram, Novartis Pharma, Basel) [25], 10 mg/kg. Control
mice received 150 mL PBS. Mice were euthanatized 1 week after the last treatment,
by carbon dioxide inhalation (80–90% in a dedicated inhalation chamber).
Repeated LPS induced lung inflammation (4 weeks)
Mice were treated intranasally with 80 mg of P. aeruginosa endotoxins/LPS [Sigma
Chemical Co., St. Louis, MO] in 40 mL PBS, under isoflurane anesthesia, once a
week for 4 weeks. Control mice were untreated. Mice were euthanatized 24 h after
the last challenge, by carbon dioxide inhalation (80–90% in a dedicated inhalation
chamber). All animals are under daily inspection by the experimenters. Humane
endpoints were used during this survival study: in case that mice unexpectedly
present obvious health problems (over 20% weight loss, signs of suffering,
difficulties in their movements and uptake of water and food, apathy) were
sacrificed, by carbon dioxide inhalation (80–90% in a dedicated inhalation
chamber).
Pseudomonas aeruginosa infection
Mice were infected with freshly prepared inoculum of P. aeruginosa strain 2310.55
of serotype IATS O11. An overnight culture in 10 mL BHI medium was prepared,
starting from the frozen stock at 37 C˚ and shaken at 150 rpm. Of this culture,
2.5 mL was taken to start a fresh 10 mL BHI culture. The culture was stopped
when an OD of about 0.4 was reached (corresponding to a bacterial titer of about
26108 bacteria/ml). Mice were anaesthetized with a low dose of intravenous
ketamine/xylazine (1.25 mg/ml/0.5 mg/mL) and 40 ml of the bacterial solution or
the corresponding vehicle solution (isotonic saline) was applied intranasally using
an ultrafine pipette tip. Mice were monitored until they woke up and evaluated
6 h and 24 h after infection.
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IL-1b antibody administration to infected mice
Mice were treated intraperitoneally, with anti-IL-1b antibody (Novartis Pharma,
Basel) [25], 200 mg/mice, 15 h and 1 h before P. aeruginosa infection. Control
mice received 150 mL PBS. Mice were euthanatized 20 h after infection, by carbon
dioxide inhalation (80–90% in a dedicated inhalation chamber).
Bacterial load in lung
Lung total weights were recorded after sacrifice and expressed as a percentage of
the body weight. Lung homogenates were prepared in 1.5 ml of isotonic saline
solution using a Dispomix tissue homogenizer (Medic Tools). Tenfold serial
dilutions of homogenate were plated on BHI agar (BHI 37g/l, Agar 15g/l) plates
(Biovalley). Plates were incubated at 37 C˚ and 5% CO2 and the numbers of CFU
were enumerated after 24 h.
Bronchoalveolar lavage (BAL)
After CO2 inhalation deep euthanasia, bronchoalveolar lavage fluid (BALF) was
collected by cannulating the trachea and washing the lung with 1 mL saline at
room temperature. The lavage fluid was centrifuged at 2,000 rpm for 10 min at
4 C˚ and the supernatant was stored at 280 C˚ for analysis. The cell pellet was
resuspended in PBS, counted in a haemocytometer chamber and cytospin
preparations were made using a Shandon cytocentrifuge (1000 rpm for 10 min).
The cells were stained with Diff-Quick (Dade Behring, Marburg, Germany) and
counted for neutrophils, macrophages, lymphocytes and eosinophils.
Total RNA extraction and RT-q-PCR from lung
Total mRNA was isolated from homogenized lung using TRI-Reagent (Sigma),
purified by RNeasy Mini Kit (Qiagen, Valencia, CA), and quantified by
NanoDrop (Nd-1000). Reverse transcription was performed in with
SuperScriptIII Kit according manufacturer’s instructions (Invitrogen). cDNA was
subjected to quantitative real-time PCR using primers for Il1b, Il6 or Ccl2
(Qiagen) and GoTaq qPCR-Master Mix (Promega). GAPDH and 18S expression
was used for normalization. Raw data were analyzed using the Relative Expression
Software Tool (REST, http://www.rest.de.com/).
Cytokine and chemokine measurement
TNF-a, IL-6, IL-1b and keratinocyte-derived chemokine (KC or CXCL-1)
concentrations in BALF and lung homogenates were measured by ELISA (Duoset
Kit; R&D Systems) according to the manufacturer’s instructions.
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MPO activity in lung
Lungs were homogenized in Dispomix [MedicTools. Zug, CH] with 1.5 mL NaCl
0.9%, and centrifuged. The supernatant was discarded. The pellet was
homogenized in 1 mL PBS - HTAB 0.5% - EDTA 1 mM. After centrifugation,
20 mL supernatant were added with: 1 mL HBSS, 200 mL of PBS - HTAB 0.5% -
EDTA 1 mM buffer, 100 mL o-Dianisidine (1.25 mg/mL) and 100 mL H2O2
0.048%. The reaction was stopped with 100 mL NaN3 1%. MPO (myeloperox-
idase) activity was determined as absorbance at 460 nm against medium.
Protein assay
Total protein concentration was analyzed in BALF, using Bradford assay with
BIORAD DC Protein assay kit (Biorad), according to the manufacturer’s
instructions.
Histology
Lungs were fixed in 4% buffered formalin, dehydrated in ethanol and embedded
in paraffin. Sections (3 mm) were stained with haematoxylin and eosin (H&E),
CAB (collagen staining) or PAS (mucus staining) and all lung sections were
evaluated by two independent observers for pathological changes, collagen
deposition, mucus production and cellular recruitment.
Statistical analysis
Statistical evaluation of differences between the experimental groups was
determined by using Mann-Whitney non-parametric test, or Log Rank test for
survival. All tests were performed with GraphPad Prism [GraphPad Software Inc.,
San Diego, CA, USA; www.graphpad.com]. A P-value ,0.05 was considered
significant and symbolized with *; ** for p,0.01 and *** for p,0.001. A P-
value.0.05 was considered not significant and symbolized with ns.
Results
1. IL-1b signaling enhances lung inflammation in F508del CFTR
mutants in response to LPS
Since LPS, P. aeruginosa [14–16] and bleomycin induced injury and inflammation
[26] are increased in F508del CFTR (d/d mice), and since the IL-1R1 pathway is
involved [20, 27] and required for the development of bleomycin-induced fibrosis
[20], we studied the role of the IL-1b pathway in the response to inflammation
and lung damage in F508del CFTR mice. In order to induce chronic lung damage,
repeated P. aeruginosa LPS challenges were performed in d/d and in double
mutant d/d x IL-1R12/2 mice, and compared to untreated WT littermate
controls. Lung analysis was performed at day 29, 24 h after the last LPS challenge.
Survival upon repeated LPS challenge was reduced to 50% in the d/d mice, while
IL-1b in P. aeruginosa Pneumonia
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100% of double KO d/d x IL-1R12/2 mice survived (Fig. 1.A). The results suggest
that in F508del CFTR mutant, the active IL-1b pathway is deleterious in response
to repeated inflammatory injury. Reduced survival of d/d mice was apparently
associated with higher loss of body weight at day 7, as compared to d/d x IL-1R12/2
mice (Fig. 1.B). Nevertheless, all surviving mice recovered their initial weight
after 4 weeks, indicating tolerance to repeated LPS challenges. LPS-induced
inflammation was confirmed by increased total cell number in BALF (macrophages
and lymphocytes) 24 h after the last challenge but no significant difference was
observed between d/d and d/d X IL-1R12/2 mice at this time point (Fig. 1.C).
Similarly, P. aeruginosa LPS also induced a recruitment of neutrophils in BALF of
both d/d and d/d X IL-1R12/2 mice (Fig. 1.C). No increase compared to untreated
WT mice of the CCL2 chemokine and IL-6 could be detected in lung homogenate
after repeated LPS challenges (Fig. 1.D and E). These results also suggest tolerance
since LPS is known to induce these cytokines after single challenge [28]. Single acute
LPS challenge is also known to induce IL-1b [29]. Indeed, the pulmonary IL-1b
production was still augmented after repeated LPS challenges in d/d mice, but to a
lesser extend in d/d x IL-1R12/2 mice (Fig. 1.F). Semi-quantitative analysis of the
lung histology indicated a distinct increase of cell infiltration, mucus production
and collagen deposition in d/d mice upon repeated LPS challenges as compared to
untreated control mice. Numerous inflammation parameters were reduced in d/d x
IL-1R12/2 mice compared to d/d, but did not reach statistical significance likely
due to the low number of surviving d/d mice (Fig. 1.A and F-J). In conclusion, the
present data support the notion that in response to LPS challenge, IL-1b participates
in inflammation and fibrosis in F508del CFTR mutants, and that genetic ablation of
IL-1R1 signaling has a protective effect.
2. Increased inflammatory response after P. aeruginosa injection
in cystic fibrosis lung
To further support this hypothesis in another model of CF pathology we used P.
aeruginosa infection, a common lung infection occurring in CF patients. We
established the model in our facility previously and showed that antibody
neutralization of LPS inhibited acute and fatal P. aeruginosa induced pneumonia
[30]. First, a P. aeruginosa (PA011) infection was performed in WT and d/d mice,
WT mice administered saline were used as control. Twenty hours after P.
aeruginosa infection, all mice developed severe pathology, as indicated by weight
loss (Fig. 2.A). Lung inflammation, analyzed by the myeloperoxidase (MPO)
activity, total cell and neutrophil counts in BALF was significantly increased in all
Fig. 1. IL-1b participates in pathologic inflammation in F508del CFTR mutants, in response to P. aeruginosa LPS. d/d and double KO d/d x IL-1R12/2
mice were treated intranasally with 80 mg of P. aeruginosa endotoxins/LPS in 40 mL PBS, once a week for 5 weeks. Untreated WT mice (UT) were used as
control. Survival is presented in (A) and body weight variation 24 h after the last LPS challenge in (B). Absolute numbers of cells, (macrophages,
lymphocytes and neutrophils) were measured in BALF 24 h after the last LPS challenge (C). CCL2 (D), IL-6 (E) and IL-1b (F) were measured in lung
homogenate. Cell infiltration was observed on H&E staining (G), mucus production on PAS staining (H) and collagen deposition on CAB staining (I).
Histopathological scores are shown in (J). n56–7 initially, n53 for d/d+LPS mice 24 h after last challenge instillation. Values are in mean +/2 SEM; * for
p,0.05 and ns for non-significant.
doi:10.1371/journal.pone.0114884.g001
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groups compared with uninfected mice (Fig. 2.B and C). The bacterial load in the
lung at 20 h did not differ between the groups (Fig. 2.D). However, bacterial load
(CFU) detected in BALF of d/d mice was two logs higher in d/d mice than in WT
mice (Fig. 2.D). Increased CFU in BALF of d/d mice was associated with
heightened neutrophil recruitment as compared with WT mice (Fig. 2.C). This
correlated with increased epithelial injury in d/d mice, compared to WT mice
(Fig. 2.E) indicating that pulmonary epithelial damage and protein release were
enhanced in d/d mice compared to WT mice (Fig. 2.G and H). KC chemokine
(CXCL1), known to attract neutrophils is increased in all groups after P.
aeruginosa infection, as compared with uninfected mice (Fig. 2.F). In d/d mice,
IL-1b and TNF-a levels were substantially higher in the lung than in WT mice.
Histological analysis showed augmented cell infiltration in d/d mice as compared
with WT mice after P. aeruginosa infection (Fig. 2.I and J).
3. IL-1b antibody neutralization attenuates P. aeruginosa-induced
inflammation
First, to study IL-1b function at steady state in the lung, we investigated the effect
of a long-lasting anti-IL-1b antibody treatment in wild type mice or in mice with
F508del CFTR mutation (d/d). Following 8-week antibody treatment, the young
adult mice (14-week-old females and males) were investigated. The treatment was
well tolerated; no mortality or morbidity was observed in any of the experimental
groups. Histological analysis did not reveal any significant differences of cell
recruitment, mucus production and collagen deposition in the lung (Fig. 3.A-C)
between WT and d/d mice treated with control PBS or anti-IL-1 antibody. Lung
mRNA expression of Il1b, Il6 and Ccl2 was assessed by qPCR and no significant
difference was found among the control and the anti-IL-1b antibody administered
groups (Fig. 3.D and E). Therefore, this investigation suggests that under basal
conditions, in the absence of stimulation, no significant difference is detected
between d/d and WT control mice. The F508del CFTR murine model (on C57BL/
6 background), displayed no significant spontaneous lung inflammation under
these conditions. Furthermore, long-term IL-1b antibody treatment had neither a
significant effect on pulmonary morphology, nor on basal expression of Il1b, Il6
and Ccl2, suggesting that IL-1b plays no significant role in steady state conditions.
Subsequently, the role of IL-1b upon P. aeruginosa infection was studied using
neutralizing antibodies in C57BL/6 mice. Mice were infected by intranasal
instillation with 106 CFU of P. aeruginosa (strain PA011) in order to induce an
acute inflammation analyzed at 20 h. To test the role of IL-1b, mice received two
Fig. 2. P. aeruginosa infection induces an increased inflammation in d/d mice. WT and d/d mice received 26105 CFU of P. aeruginosa PA011
intranasally, and WT mice treated with NaCl 0.9% were used as control. Body weight variation 20 h after infection is shown in (A). Myeloperoxidase activity
was quantified (B) and absolute numbers of cells; (macrophages and neutrophils) were measured in BALF (C). Bacterial load (total CFU) was determined in
BALF and in lung homogenate (D). Total protein concentration was evaluated in BALF (E) and KC (F), IL-1b (G) and TNF-a (H) were measured in lung
homogenate. Cell infiltration was observed on H&E stained slide (I) and scored (J). (n55–6) Values are in mean +/2 SEM; * for p,0.05; ** for p,0.01 and
*** for p,0.001. ns for non-significant.
doi:10.1371/journal.pone.0114884.g002
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Fig. 3. Anti-IL-1b antibody treatment has no significant effect on lung ultrastructure, nor on IL-1b, IL-6
and CCL2 mRNA production in lungs.Wild type (WT) and F508del CFTR mutation homozygote (d/d) mice
(14-week-old females and males) were treated intra-peritoneally, once a week for 8 weeks, an anti-IL-1b
antibody (10 mg/kg), or PBS. Mice were euthanatized 1 week after the last treatment and lung structure was
observed on H&E stained slides observed at620 magnification (A). Cellular infiltration (B) was quantified on
these H&E slides and mucus production (C) was analyzed on CAB stained lung slides. Lung injury score was
recorded in anti-IL-1b antibody treated mice compared with PBS treated mice. (D and E) mRNA production of
IL-1b, IL-6 and CCL2 was measured, and normalized with 2 housekeeping gene expression (Hprt1 and
Gapdh). The effect of anti-IL-1b antibody treatment compared to PBS control in WTand d/d animals is shown
in (D), and the effect of F508del CFTR mutation compared to WT is shown in (E). (n56–7)
doi:10.1371/journal.pone.0114884.g003
IL-1b in P. aeruginosa Pneumonia
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Fig. 4. IL-1b participates in P. aeruginosa-induced inflammation at 20 h in WT mice. WT mice received 106 CFU of P. aeruginosa PA011 intranasally,
and WT mice treated with NaCl 0.9% were used as control. A group of WT mice was also treated intraperitoneally with anti-IL-1b antibody, 200 mg/mice,
15 h and 1 h before infection. Body weight variation 20 h after infection is shown in (A). Bacterial load was determined in BALF and in lung homogenate (B),
myeloperoxidase activity was quantified (C) and absolute numbers of cells, (macrophages and neutrophils) were measured in BALF (D). Protein
concentration was evaluated in BALF (E) and IL-1b (F), KC (G), TNF-a (H) and IL-6 (I), were measured in BALF and in lung homogenate. Cell infiltration was
observed on H&E stained slide (J) and scored (K). (n55–6) Values are in mean +/2 SEM; * for p,0.05; ** for p,0.01 and *** for p,0.001. ns for non-
significant.
doi:10.1371/journal.pone.0114884.g004
IL-1b in P. aeruginosa Pneumonia
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peritoneal injections of 200 mg neutralizing antibodies 15 h and 1 h before
infection. As reported before (Figure 2 and in [30]), infection of C57BL/6 mice
with P. aeruginosa caused a rapid weight loss (Fig. 4.A), with a bacterial load of
104 CFU in BALF and total lung (Fig. 4.B). P. aeruginosa infection provoked
neutrophil recruitment (revealed by myeloperoxidase activity measurement and
cell counts in BALF), and epithelial damage suggested by an increase of proteins in
BALF in all groups post infection (Fig. 4.C-E). However, IL-1b neutralization had
a distinct effect on infection and lung inflammation. Indeed, IL-1b blockade
significantly reduced bacterial load in BALF, and to a lesser extent in lung
(Fig. 4.B), suggesting a substantial difference in bacterial clearance between the
two groups. This was correlated with a decrease in neutrophil recruitment
(Fig. 4.C and D) and an inhibition of protein in BALF as measure of epithelial
damage (Fig. 4.E). Moreover KC and TNF-a production in BALF were
diminished (Fig. 4.G and H), whereas IL-6 was not modified (Fig. 4.I). In
agreement with this, histological analysis showed reduced cell infiltration in anti-
IL-1b treated mice as compared with WT untreated mice after P. aeruginosa
infection (Fig. 4.J and K). These data suggest that IL-1b antibody neutralization
may attenuate P. aeruginosa-induced acute lung inflammation.
Discussion
CF patients display increased susceptibility to chronic infections with opportu-
nistic bacteria, excessive lung inflammation and fibrosis leading to fatal loss of
function eventually [6]. P. aeruginosa has been shown to induce IL-1b through
NLRC4 inflammasome activation [9, 10]. CFTR deficient mice were found to be
more susceptible to P. aeruginosa infection (acute [14, 15] and chronic [16]) and
have an exacerbated inflammatory response to LPS and P. aeruginosa.
Furthermore, F508del CFTR mutant alveolar macrophages display an enhanced
IL-1b production in response to LPS stimulation [18]. Thus, we were interested in
clarifying the role of IL-1b in the resolution of P. aeruginosa infection, in a murine
model with the most common CF mutation F508del CFTR [21–23]. Here, we
show that, after P. aeruginosa infection, excessive activation of IL-1b in F508del
CFTR (d/d) mice compared to WT was accompanied by increased CFU in BALF,
inflammation and lung damage. Further we show that a therapeutic antibody
administration attenuates inflammatory response in an acute model of infection
using WT mice.
In CF patients bacterial infections persist and their chronicity facilitates lung
inflammation, and subsequent tissue remodeling with severe loss of function [1].
CF lungs display excessive immune response, with increased neutrophil
recruitment [8]. We first investigated the role of IL-1b under pathologic
conditions, induced by repeated P. aeruginosa-LPS challenges. We observed LPS-
induced mortality in d/d mice, that was absent in d/d x IL-1R12/2 double
mutants, and a higher inflammation in d/d mice compared to the double mutant,
suggesting a detrimental role of the IL-1R1 pathway in LPS-challenged d/d mice
IL-1b in P. aeruginosa Pneumonia
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(Fig. 1). The deficiency in IL-1R1 apparently protected the mice against LPS-
induced mortality in d/d mice. P.aeruginosa-LPS challenges were responsible for
leucocyte recruitment, including neutrophils. Despite increased cell infiltration in
the lung of d/d mice, collagen deposition and mucus production were only
slightly increased after multiple LPS challenges. Repeated LPS challenges did not
cause epithelial damage and chronic inflammation, which we explain by tolerance
induction [31], that is the reason to switch to P. aeruginosa infection.
No spontaneous inflammation was found in young adult F508del CFTR mutant
on C57BL/6 genetic background under our conditions. Whereas signs of
inflammation and tissue remodeling develop early in most CF patients [32],
results on basal inflammation in murine models are variable [23]. These data are
consistent with published data on the absence of spontaneous pathology such as
mucus plugging, neutrophil accumulation or bronchiectasis, in young mice
deficient or mutated for the Cftr gene [15, 33–35], but neutrophilic inflammation
has been reported in absence of infection [36, 37]. Spontaneous lung pathology
development seems to be dependent on the age of mice [37], genetic background
and animal facility health status [23]. However, in CF mutant mice challenged
with pro-inflammatory agents (P. aeruginosa, LPS) enhanced injury and
inflammation compared to wild type was reported in several independent studies
[14, 15, 26, 38].
Therefore, to get closer to a model of lung infections that occur in CF patients,
we used an acute P. aeruginosa infection model, which is the most current
pathogen found in CF patient [7], in F508del CFTR mice. Twenty hours after P.
aeruginosa infection, d/d mice displayed increased neutrophil recruitment in
BALF as compared with WT mice (Fig. 2). They also showed an increase in
bacterial load and cytokine production, such as IL-1b and TNF-a, in BALF. These
results suggest a higher sensitivity to infection in d/d mice, consistent with
previous studies in CFTR mutant mice, showing an augmentation of bacterial
load and production of pro-inflammatory cytokines after P. aeruginosa infection
[14, 15, 38]. The enhanced production of IL-1b compared to WT after infection
was associated with increased epithelial damage, cell infiltration and CFU (Fig. 2).
Then, we analyzed the effect of IL-1b neutralization at steady state in the lung. We
found that in d/d as well as in WT mice, IL-1b antibody had no significant effect
on survival. Furthermore d/d and WT mice displayed no difference in basal Il1b
mRNA expression, and repeated anti-IL-1b antibody administration had no
significant effect on basal inflammatory parameters and cytokine production.
However, our data suggest that IL-1b may cause an excessive and pathologic
inflammation in challenged CF mutant lungs. IL-1b over-expression in d/d mice
infected with P. aeruginosa was accompanied by a higher bacterial load. Indeed,
excessive production of inflammatory cytokines has been associated with bacterial
persistence in other studies as well. High concentrations of cytokine, such as IL-
1b, IL-6 or TNF-a, enhance intracellular and extracellular bacterial growth of P.
aeruginosa, or S. aureus in the presence of monocytes [39, 40]. Furthermore, IL-1b
release was linked to mortality in a murine model of P. aeruginosa infection after
thermal injury [41].
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Therefore, we tested the effect of a therapeutic antibody against murine IL-1b
in our acute P. aeruginosa infection model in WT mice. IL-1b neutralization has
been successfully tested previously with this antibody in a model of intestinal
inflammation [25]. Twenty hours after P. aeruginosa infection, IL-1b antibody
administration caused a decrease in the inflammatory parameters and in bacterial
load, as compared with NaCl-treated mice. This is consistent with studies by
Schultz et al. who showed that inhibition of the IL-1R1 pathway by either the IL-
1R1 mutation or application of the IL-1b antagonist IL-1RA improved
antibacterial host defense and reduced pro-inflammatory cytokine production
[42]. Reduced neutrophil recruitment by IL-1b neutralization could be due to
reduced endothelial activation, as proinflammatory cytokines activate endothelial
cells. For instance, TNF-a and IL-17 synergize to induce in cultured endothelial
cells the expression of P- and E-selectin, as well as neutrophil chemokines,
increasing neutrophil transmigration [43]. IL-1b produced by activated mono-
cytes was shown to augment the expression of adhesion molecules (ICAM-1, E-
selectin) in vitro [44]. Thus, the diminished leucocyte recruitment we observe with
IL-1b neutralization could be related to a reduced endothelial activation.
Abnormal recruitment and metabolic adaptation of neutrophils in human CF
airways has been demonstrated [45], the molecular mechanism remains to be
established but likely involves IL-1b signaling based on the arguments mentioned
above. We cannot exclude a role of lung fibroblasts and myoblasts. Indeed, IL-1b
stimulated human cardiac fibroblasts overexpress adhesion molecules and
neutrophil chemoattractant [46].
In conclusion we propose that the IL-1b pathway is critical to drive excessive
and detrimental inflammation in F508del mouse model of CF. We show here that
antibody neutralization of IL-1b is well tolerated in mice, has no effect on the
unchallenged lung in WT or F508del CFTR mice, whereas it can reduce pathology
induced by acute bacterial lung infection.
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